Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Post-Mkt 01-13 19:31:04 EST

25.93

+0.26

+1.01%

盘后25.93

+0.000.00%

17:38 EST

High26.50	Low25.15	Vol855.75K
Open25.68	D1 Closing25.67	Amplitude5.28%
Mkt Cap1.72B	Tradable Cap1.38B	Total Shares66.45M
T/O22.20M	T/O Rate1.61%	Tradable Shares53.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":25.93,"timestamp":1768338000000,"preClose":25.67,"halted":0,"volume":855749,"hourTrading":{"tag":"盘后","latestPrice":25.93,"preClose":25.93,"latestTime":"17:38 EST","volume":17422,"amount":451752.46,"timestamp":1768343882457},"delay":0,"floatShares":53206696,"shares":66449471,"eps":-3.381938,"marketStatus":"Post-Mkt","change":0.26,"latestTime":"01-13 19:31:04 EST","open":25.68,"high":26.5,"low":25.145,"amount":22196763.284596,"amplitude":0.052785,"askPrice":26.44,"askSize":75,"bidPrice":25.43,"bidSize":78,"shortable":3,"etf":0,"ttmEps":-3.381938,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768352400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":25.67,"preHourTrading":{"tag":"盘前","latestPrice":25.76,"preClose":25.67,"latestTime":"09:29 EST","volume":606,"amount":15760.986168,"timestamp":1768314587098},"postHourTrading":{"tag":"盘后","latestPrice":25.93,"preClose":25.93,"latestTime":"17:38 EST","volume":17422,"amount":451752.46,"timestamp":1768343882457},"volumeRatio":1.128495,"impliedVol":0.6525,"impliedVolPercentile":0.7251},"requestUrl":"/m/hq/s/CLDX/tweets","defaultTab":"tweets","newsList":[{"id":"2602376848","title":"Celldex (CLDX) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376848?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:46","pubTimestamp":1767962763,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst reiterated a Buy rating on Celldex today and set a price target of $48.00. Currently, the analyst consensus on Celldex is...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/celldex-cldx-gets-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/celldex-cldx-gets-a-buy-from-mizuho-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","CLDX","BK4139","BK4207"],"gpt_icon":0},{"id":"2602321060","title":"Barclays Remains a Sell on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602321060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602321060?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:45","pubTimestamp":1767951950,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Sell rating on Celldex, with a price target of $24.00. According to TipRanks, D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-sell-on-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-sell-on-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2601356177","title":"Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356177","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601356177?lang=en_us&edition=fundamental","pubTime":"2026-01-08 15:45","pubTimestamp":1767858353,"startTime":"0","endTime":"0","summary":"Jan 8 (Reuters) - BAYER AG ::*BAYER AND SOUFFLE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE CELL-SPECIFIC HEART-TARGETED SIRNA THERAPY*COLLABORATION FOCUSES ON DEVELOPING POTENTIAL BEST I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nRSD1SsYSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2593017346","title":"Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593017346","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593017346?lang=en_us&edition=fundamental","pubTime":"2025-12-22 02:21","pubTimestamp":1766341277,"startTime":"0","endTime":"0","summary":"In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 antihistamines or biologics, enrolling about 240 patients across approximately 75 sites in 7 countries with complete response at Week 12 as the primary endpoint.\nThis late-stage program builds directly on earlier placebo-controlled Phase 2 data showing rapid, durable clinical responses and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/is-celldex-cldx-using-barzolvolimabs-phase-3-urticaria-bet-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2592291272","title":"Celldex Therapeutics Is Maintained at Underweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2592291272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592291272?lang=en_us&edition=fundamental","pubTime":"2025-12-18 01:49","pubTimestamp":1765993740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 12:49 ET (17:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2590126955","title":"Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590126955","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590126955?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:27","pubTimestamp":1765463259,"startTime":"0","endTime":"0","summary":"Earlier this week, Celldex Therapeutics announced it has begun a global Phase 3 EMBARQ trial of barzolvolimab in adults with cold urticaria and symptomatic dermographism who remain symptomatic despite H1 antihistamines or biologics, enrolling about 240 patients across 75 sites in 7 countries.\nThis marks the second Phase 3 program for barzolvolimab and follows a prior placebo-controlled Phase 2 study where the drug achieved statistically significant improvements in provocation test responses...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/should-celldexs-global-phase-3-embarq-trial-for-barzolvolima","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/should-celldexs-global-phase-3-embarq-trial-for-barzolvolima","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","CLDX","BK4139","ISBC"],"gpt_icon":0},{"id":"2590349391","title":"BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349391","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349391?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:02","pubTimestamp":1765285376,"startTime":"0","endTime":"0","summary":"BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic DermographismDec 9 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX INITIATES GLOBAL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2590349398","title":"Celldex Therapeutics Inc - Data From Open Label Extension Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349398?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:01","pubTimestamp":1765285308,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0K0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2590349352","title":"Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349352?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:01","pubTimestamp":1765285308,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2590057365","title":"Celldex SVP & General Counsel Freddy A. Jimenez Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590057365","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590057365?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:21","pubTimestamp":1765228874,"startTime":"0","endTime":"0","summary":"Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9PyxKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Celldex SVP & General Counsel Freddy A. Jimenez Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2585123076","title":"How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2585123076","media":"Simply Wall St.","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585123076?lang=en_us&edition=fundamental","pubTime":"2025-11-22 03:12","pubTimestamp":1763752356,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics recently reported third-quarter 2025 results, including a larger net loss of US$67.04 million and a loss per share of US$1.01, alongside a significant decrease in nine-month revenue.\nThe company also announced the appointment of Teri Lawver as Chief Commercial Officer, bringing decades of commercial and immunology experience to its leadership team after the retirement of Richard Wright.\nWe'll explore how the company's increased losses and key commercial leadership...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/how-investors-may-respond-to-celldex-therapeutics-cldx-leade","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/how-investors-may-respond-to-celldex-therapeutics-cldx-leade","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CLDX","ISBC","BK4211"],"gpt_icon":0},{"id":"2584910703","title":"Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910703","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910703?lang=en_us&edition=fundamental","pubTime":"2025-11-19 16:35","pubTimestamp":1763541312,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) shares have experienced some short-term swings lately, and investors may be wondering what is behind these moves. Over the past month, the stock dipped about 8%, even as its revenue has grown almost 80% year over year.\nSee our latest analysis for Celldex Therapeutics.\nCelldex Therapeutics has seen bursts of momentum and reversals, with a 16.2% share price return over the past 90 days helping to balance out its 1-year total shareholder return of -3.1%. Investors...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-assessing-valuation-after-recent-r","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-assessing-valuation-after-recent-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2584663069","title":"Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2584663069","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584663069?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:26","pubTimestamp":1763501206,"startTime":"0","endTime":"0","summary":"Michael Heltzen, CEO of eXoZymes Inc., was recently interviewed by Lou Basenese on episode #2 of \"The Upside.\" During the interview, Heltzen detailed the company's breakthrough in translating cell-free enzymatic pathway technology from the lab to new product lines already reaching the market. He emphasized that eXoZymes is currently the only company able to run entire enzymatic pathways outside of cells, distinguishing its platform from competitors. The discussion also touched on the challenges of synthetic biology and the company's accelerating innovation in creating new-to-nature molecules with significant pharmaceutical potential. The URL for the full speech/interview was not provided in the document.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLY01Tv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","EXOZ","BK4139"],"gpt_icon":0},{"id":"2583884685","title":"Celldex Therapeutics Files Initial Beneficial Ownership Statement for SVP & Chief Commercial Officer Teri Lawver","url":"https://stock-news.laohu8.com/highlight/detail?id=2583884685","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583884685?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:06","pubTimestamp":1762981585,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Teri L. Lawver as the beneficial owner, serving as the company's Senior Vice President and Chief Commercial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8GZ8RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2582360401","title":"Celldex Therapeutics Is Maintained at Underweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582360401?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:13","pubTimestamp":1762873980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 10:13 ET (15:13 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2582361145","title":"Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582361145?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:15","pubTimestamp":1762866939,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA reiterated a Buy rating on Celldex today and set a price target of $58.00. According to TipRanks, Thompso...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","SF"],"gpt_icon":0},{"id":"2582033369","title":"Mizuho Securities Remains a Buy on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582033369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582033369?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:45","pubTimestamp":1762865152,"startTime":"0","endTime":"0","summary":"In a report released today, from Mizuho Securities maintained a Buy rating on Celldex, with a price target of $48.00. In addition to Mizuho Securit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","CLDX","BK4139","MFG"],"gpt_icon":0},{"id":"2582351304","title":"Barclays Sticks to Its Sell Rating for Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582351304","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582351304?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:56","pubTimestamp":1762851372,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Sell rating on Celldex, with a price target of $21.00. Darout covers the Health...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-sell-rating-for-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-sell-rating-for-celldex-cldx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2582832873","title":"Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582832873","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582832873?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:46","pubTimestamp":1762811181,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.91) by 10.87 percent. This is a 57.81 percent decrease over losses of $(0.64) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48768020/celldex-therapeutics-q3-eps-1-01-misses-0-91-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2582388013","title":"Top News Today/Canada: Barrick's Interim CEO Gets to Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388013?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:30","pubTimestamp":1762810200,"startTime":"0","endTime":"0","summary":"Barrick Looks to Get Handle on North American Operations, Find Growth. Barrick Mining is diving into how its core gold operations in Nevada are being run and is looking for opportunities to boost production, steps that come after parting ways with its former chief executive.Mark Hill, Barrick's interim CEO, said that the mining company is determined to grow and not just replace the resources it digs up, and to produce gold and copper safely.Since taking on the role and being named chief operating officer in late September, Hill said he has met with Barrick's teams around the world. He also spent several weeks in Nevada, which alongside an asset in the Dominican Republic, is a focus of the company's review.Barrick Looking to Reset Safety Culture  Barrick Continues Efforts to Free Workers Jailed in Mali. Burger King Strikes Joint Venture to Double Presence in China. C2AE offers a range of engineering services to clients including state and local governments, transportation agencies, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","KALV","BK4137","BK4079","MGTX","NRDE","MGNX","CLDX","BK4139","SLSN","PRLD","BK4539","ACCS","LPTH","BK4138","IPSC","STXS","BK4099","BK4505","BK4179","BK4551","FTHM","GNPX","NMM","CRBU","ATRA","LU0205193047.USD","WKHS","AMTX","PVLA","BK4168","SND","BK4134","IE00BFMHRM44.USD","ATOS","BK4082","SYPR","GIFI","SSTI","BK4547","CENN","DOX","WHLM","QUIK","BK4021","EVI","MVIS","BK4109","BK4023"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":-0.0669},{"period":"3month","weight":-0.0302},{"period":"6month","weight":0.1171},{"period":"1year","weight":0.0542},{"period":"ytd","weight":-0.0549}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.124394},{"month":2,"riseRate":0.410256,"avgChangeRate":-0.007148},{"month":3,"riseRate":0.461538,"avgChangeRate":0.003323},{"month":4,"riseRate":0.487179,"avgChangeRate":0.002303},{"month":5,"riseRate":0.282051,"avgChangeRate":-0.021096},{"month":6,"riseRate":0.5,"avgChangeRate":0.145989},{"month":7,"riseRate":0.425,"avgChangeRate":-0.012999},{"month":8,"riseRate":0.375,"avgChangeRate":-0.027935},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}